Senior Director, HEOR/RWE GI

About the role

The Senior Director, HEOR/RWE is a leader within the organization, responsible for developing an HEOR/RWE strategy and executing HEOR plans and activities related to Revolution Medicines assets intended for use in pancreatic and colorectal cancer. They will be accountable for demonstrating the value of Revolution Medicines products to healthcare organizations, allowing them to make informed decisions. They will work closely with the Medical Affairs team as well as other cross-functional teams to optimize the Integrated Evidence Plan (IEP) and to deliver evidence supporting the use of Revolution Medicines products. The candidate must also be able to provide input and strategic guidance on the global value of the product as well as have demonstrated success in evidence generation globally. The Senior Director HEOR/RWE will participate with the matrix team across the function to ensure alignment of all activities with the strategic and tactical plans. This individual will serve as an HEOR expert internally and also while representing RevMed externally at industry conferences. This is an exceptional opportunity to contribute to the advancement of healthcare by providing evidence that can shape the future of patient care in oncology. Reporting to the Executive Director of HEOR/RWE GI, the Senior Director, HEOR/RWE will: Develops and evolves product HEOR/RWE strategy, including integration with development and market access planning. Aligns with Medical Affairs and Development leadership to design research and delivers evidence consistent with the medical strategy and IEP. Delivers HEOR/RWE tactics with quality and in alignment with agreed upon timing. Provides HEOR/RWE leadership on matrix teams and working groups. Leads enterprise partnerships with payers, HTA agencies, and global consortia to help shape access strategy, policies, evidence standards, and evidence generation activities. Works with the HEOR/RWE and Medical Affairs leadership to ensure critical value insights are communicated to key internal teams. Provides HEOR evidence which addresses the needs and expectations of key stakeholders such as patients, healthcare providers, payers and Health Technology Assessment (HTA) agencies. Effectively presents research findings to internal and external stakeholders to improve internal decision making and to promote wider adoption of research findings across external stakeholders. Facilitates the communication of the value proposition of Revolution Medicines' portfolio, allowing key healthcare and formulary professionals to make informed therapeutic decisions. Engage sand collaborate with external partners including payers, health care providers, thought leaders, patient advocates, and decision-makers to establish/maintain strong partnerships and gather insights into research programs. Facilitates and implement real-world research partnership engagements with leading healthcare, academic and payer organizations to co-create value evidence and help drive evidence-based optimal care. Stays up to date with and add to the advancements in health economics methodologies and best practices; support the build of disease area HEOR/RWE disease area capability, establishing best practices, external visibility, and functional excellence across the medical affairs network. Identifies and interface with HEOR & RWE experts and organizations, profiles data sources and related organizations as they relate to Revolution Medicines' portfolio and therapeutic areas. Closely monitors new trends in health policy and payer environment, assess competitive data gaps and communicate to the organization, to help Revolution Medicines build industry-leading capabilities and be on the cutting edge of evidence-based medicine and HEOR research. Required Skills, Experience and Education: Deep expertise in health economics, outcomes research, patient-reported outcomes or related fields in the biotechnology or pharmaceutical industry. Experience in oncology HEOR and RWE development. Minimum 10-13 years of relevant experience with an advanced degree in a relevant field (MD, PhD, PharmD). Track record of high impact publications in HEOR/RWE topics. Proven success

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience